Investing.com - Biogen (NASDAQ:BIIB) reported on Tuesday first quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Biogen announced earnings per share of $3.62 on revenue of $2.53B. Analysts polled by Investing.com anticipated EPS of $4.34 on revenue of $2.5B.
Biogen shares are down 13% from the beginning of the year and are trading at $207.32 , down-from-52-week-high.They are broadly in line with the S&P 500 which is down 12.82% from the start of the year.
Biogen follows other major Healthcare sector earnings this month
Biogen's report follows an earnings beat by UnitedHealth on April 14, who reported EPS of $5.49 on revenue of $80.15B, compared to forecasts EPS of $5.36 on revenue of $78.73B.
J&J had beat expectations on April 19 with first quarter EPS of $2.67 on revenue of $23.43B, compared to forecast for EPS of $2.59 on revenue of $23.62B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar